Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
07:15am, Tuesday, 30'th Jul 2024
LAUSANNE, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced
7 Growth Stocks to Buy for Under $5 for Massive Gains
03:24pm, Thursday, 11'th Jul 2024
With growth stocks under $5, the focal point is rather obvious: putting woodwork on the ball as aggressively as possible. Of course, swinging for the fences comes with significant risks.
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
02:00am, Monday, 08'th Jul 2024
LONDON, July 08, 2024 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
07:15am, Thursday, 27'th Jun 2024
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® I
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
02:31pm, Thursday, 13'th Jun 2024
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of m
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Monday, 03'rd Jun 2024
LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
07:15am, Thursday, 30'th May 2024
LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies Gl
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
07:15am, Wednesday, 15'th May 2024
LAUSANNE, Switzerland, May 15, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the H.C. Wai
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
07:15am, Thursday, 09'th May 2024
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024 RBC
ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript
11:04am, Monday, 06'th May 2024
ADC Therapeutics SA (NYSE:ADCT ) Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Nicole Preiss-Riley - Executive Director, Head of Communications Ameet Mallik - CEO Kriste
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
08:21am, Monday, 06'th May 2024
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.56 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.74 per share a year ago.
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
07:30am, Monday, 06'th May 2024
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
06:10am, Monday, 06'th May 2024
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%) 1 compared to 1Q 2023
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA ®
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Wednesday, 01'st May 2024
LAUSANNE, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 147,600 of the Company'
